Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
ReplyLetter

Dr. Charles-Schoeman and E. Bananis Reply

CHRISTINA CHARLES-SCHOEMAN and EUSTRATIOS BANANIS
The Journal of Rheumatology November 2018, 45 (11) 1605; DOI: https://doi.org/10.3899/jrheum.180489
CHRISTINA CHARLES-SCHOEMAN
Associate Professor of Medicine, University of California, Los Angeles, California;
MD, MS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
EUSTRATIOS BANANIS
Pfizer Inc., New York, New York, USA.
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: stratis.bananis@pfizer.com
  • Article
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

To the Editor:

We thank Professor Boers for his interest1 in our study2 and are grateful for the opportunity to respond to his queries.

Our posthoc analysis investigated the effect of concomitant glucocorticoid (GC) use on clinical and radiographic outcomes in phase III studies of methotrexate (MTX)-naive patients receiving tofacitinib or MTX as monotherapy (ORAL Start), disease-modifying antirheumatic drug (DMARD)–inadequate responder (IR) patients receiving tofacitinib or placebo as monotherapy (ORAL Solo), and MTX-IR and DMARD-IR patients receiving tofacitinib or placebo in combination with background conventional synthetic DMARD (ORAL Sync, ORAL Standard, ORAL Scan, and ORAL Step).

We noted with interest that our findings for MTX with or without GC were similar to those previously published by Professor Boers in this journal3. In our analysis, radiographic progression data were reported only in ORAL Start (NCT01039688), a 24-month study of tofacitinib versus MTX in MTX-naive patients (n = 956). In this study, radiographic efficacy and rates of radiographic nonprogression in tofacitinib-treated patients were similar regardless of GC use; however, concomitant use of GC with MTX appeared to inhibit radiographic progression to a greater extent than MTX alone. Patients treated with MTX without GC had the highest least squares mean change from baseline in the van der Heijde modified total Sharp score (mTSS) through Month 24 among all the treatment groups; however, the 95% CI overlapped between the 2 MTX subgroups (MTX only vs MTX + GC).

In response to Professor Boers’ query regarding the statistical tests used, these posthoc analyses were exploratory in nature and no formal statistical comparisons between the subgroups were performed; rather, the data were analyzed by descriptive statistics only and trends were reported. We can confirm that changes from baseline in mTSS were measured at months 6, 12, and 24, and that an overall assessment spanning the full 24-month period, inclusive of these 3 visits, was performed in the mixed-model separately for each subgroup.

We also wish to clarify that while 5 of the 6 phase III studies in this posthoc analysis included a placebo arm, patients receiving placebo blindly advanced to tofacitinib 5 or 10 mg BID at Month 3 or Month 6; therefore, no patients still took placebo at Month 24. It should also be noted that ORAL Start compared tofacitinib 5 mg or 10 mg BID versus MTX, and did not include a placebo arm.

Footnotes

  • Dr. Charles-Schoeman received research grants from AbbVie, BMS, and Pfizer Inc., and consulting fees from Regeneron-Sanofi. E. Bananis is an employee and shareholder of Pfizer Inc.

  • This work was funded by Pfizer Inc. Medical writing support, under the direction of the authors, was provided by Jennifer Higginson, PhD, of CMC Connect, a division of Complete Medical Communications Ltd., Glasgow, UK, and was funded by Pfizer Inc., in accordance with Good Publication Practice (GPP3) guidelines.

REFERENCES

  1. 1.↵
    1. Boers M
    . Effects of co-medication with glucocorticoids in biologics trials. J Rheumatol 2018;45:1605.
    OpenUrlFREE Full Text
  2. 2.↵
    1. Charles-Schoeman C,
    2. van der Heijde D,
    3. Burmester GR,
    4. Nash P,
    5. Zerbini CAF,
    6. Connell CA,
    7. et al.
    Effect of glucocorticoids on the clinical and radiographic efficacy of tofacitinib in patients with rheumatoid arthritis: a posthoc analysis of data from 6 phase III studies. J Rheumatol 2018;45:177–87.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Boers M,
    2. Aletaha D,
    3. Mela CM,
    4. Baker DG,
    5. Smolen JS
    . Glucocorticoid effect on radiographic progression in placebo arms of rheumatoid arthritis biologics trials. J Rheumatol 2016;43:1024–6.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 45, Issue 11
1 Nov 2018
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Dr. Charles-Schoeman and E. Bananis Reply
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Dr. Charles-Schoeman and E. Bananis Reply
CHRISTINA CHARLES-SCHOEMAN, EUSTRATIOS BANANIS
The Journal of Rheumatology Nov 2018, 45 (11) 1605; DOI: 10.3899/jrheum.180489

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Dr. Charles-Schoeman and E. Bananis Reply
CHRISTINA CHARLES-SCHOEMAN, EUSTRATIOS BANANIS
The Journal of Rheumatology Nov 2018, 45 (11) 1605; DOI: 10.3899/jrheum.180489
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Footnotes
    • REFERENCES
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • The Incidence of Herpes Zoster Is Increased in the Population of Patients With Rheumatoid Arthritis
  • Dr Singer et al reply
  • Psychosocial Factors Significantly Contribute to Joint Pain Persistence in Psoriatic Arthritis
Show more letter

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2023 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire